- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01655199
Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With Chronic Obstructive Pulmonary Disease (CODEx)
September 17, 2013 updated by: Benoit Borel, Laval University
Measurement of Exertional Dyspnea in the Primary Care Setting in Patients With COPD, Phase III: Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With COPD
During the previous phases of the project (Phase I and II), two new field tests have been designed and validated for an integration in a primary care setting in Chronic Obstructive Pulmonary Disease (COPD).
These new field tests are 3-min paced-walk test (3MPWT) and 3-min paced step test (3MPST).
If the validity and sensitivity of the TM3 could be highlighted, particularly by the reduction of dyspnea level following bronchodilatation, Phase II highlight that the 3MPST does not allow to detect this decrease of dyspnea after bronchodilatation.
The use of too high step rates could explain these results through a hypothesis relative to neuromechanical coupling of dyspnea.
The main objective of this trial is to follow the investigations on the sensitivity of 3MPST to detect the effects of pharmacological intervention on the exertional dyspnea in COPD patient.
The hypothesis of this work is that the use of lower step rates cadences could allow to detect an improvement of exertional dyspnea following treatment-induced bronchodilatation, contrary to higher step rates.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
For this project, 40 patients with COPD will be recruited in 2 centres (in the Institute of Cardiology and Pneumology of Quebec and in the Chest Institute of Montreal).
For each patient, three visits will be performed.
During the first visit, baseline pulmonary function and maximal exercise capacity will be evaluated and the patients will be familiarized with step test proceedings.
Between the different visits, a 3-7 days period will be respected.
During the second and the third visits, 4 step tests will be performed at 4 different rates, following one of the two conditions (placebo or bronchodilatation).
This project will propose two randomization levels.
The first randomization will be relative to the choice of the condition used during the second visit (placebo ou bronchodilatation) and the second one for the rates order (14, 16, 20, 24 steps/min).
During each performed exercise, cardiorespiratory and pulmonary parameters will be measured using a portable system.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: François Maltais, M.D
- Phone Number: 418-656-4747
- Email: Francois.Maltais@fmed.ulaval.ca
Study Contact Backup
- Name: Benoit Borel, Ph.D
- Phone Number: 3995 418-656-8711
- Email: benoit.borel@criucpq.ulaval.ca
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada
- Recruiting
- Montreal Chest Institute - McGill University
-
Contact:
- Jean Bourbeau, M.D
- Email: jean.bourbeau@mcgill.ca
-
Contact:
- Hélène Perrault, Ph.D
- Email: helene.perrault@mcgill.ca
-
Sub-Investigator:
- Jean Bourbeau, M.D
-
Québec, Quebec, Canada
- Active, not recruiting
- Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Université Laval
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age higher than 50 years old
- smoking history ≥ 10 packs/year
- post-bronchodilator FEV1 between 30 and 80% of the predicted value and FEV1/FVC lesser than 70% as assessed in previous pulmonary function test (corresponding to GOLD stages II and III)
Exclusion Criteria:
- respiratory exacerbation within the preceding 6 weeks
- asthmatic condition
- significant O2 desaturation (SaO2 < 85%) at rest or during exercise
- presence of another pathology that could influence exercise tolerance or may prevent the realization of the step test
- subject having a pacemaker
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: COPD group
Moderate and/or severe COPD patients, corresponding to GOLD stages II and III.
|
For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design.
For the visit 3, the other intervention drug will be assigned.
The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptom perception
Time Frame: change from baseline in Borg Scale at 3 min of exercise
|
Patients will be asked to score their dyspnea and leg discomfort perception using a 10-point Borg scale.
|
change from baseline in Borg Scale at 3 min of exercise
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiac and ventilatory outcomes
Time Frame: Change from baseline at 3 minutes of exercise
|
Metabolic, cardiac and ventilatory parameters will be measured using a metabolic cart.
Principal outcomes will be oxygen uptake (VO2), carbon dioxide output (VCO2), ventilation (VE), breathing frequency (BF), tidal volume (Vt) and heart rate (HR).
|
Change from baseline at 3 minutes of exercise
|
Inspiratory capacity
Time Frame: Change from baseline at the end of the exercise.
|
Inspiratory capacity will be measured at rest and at the end of the 3-min step test (immediately following the assessment of dyspnea at 3 minutes).
|
Change from baseline at the end of the exercise.
|
Respiratory pressures and diaphragm EMG
Time Frame: Change from baseline at 1, 2 and 3 minutes of exercise
|
Tidal excursion in pleural pressure will be measured using an oesophageal balloon-catheter system that will be positioned using standardized technique (n=40).
Gastric and transdiaphragmatic pressures as well as the diaphragm electromyogram will be recorded in the 20 subjects studied at McGill University using a multipair esophageal electrode-balloon catheter.
|
Change from baseline at 1, 2 and 3 minutes of exercise
|
Pulmonary function
Time Frame: At baseline and 60-min after the nebulization of either placebo and bronchodilator
|
Pulmonary function will be measured by spirometry and plethysmography in the initial visit.
In the subsequent visits, pulmonary function will be evaluated by spirometry before and 60-min after the nebulization of either placebo or bronchodilator.
|
At baseline and 60-min after the nebulization of either placebo and bronchodilator
|
Maximal oxygen consumption
Time Frame: Change from baseline at 1, 2 and 3 minutes of exercise
|
Exercise capacity will be directly assessed following an incremental cycle exercise test.
The exercise capacity was defined as the maximal oxygen consumption (VO2 peak, ml/kg/min) by direct measurements of gas exchanges.
|
Change from baseline at 1, 2 and 3 minutes of exercise
|
Maximal inspiratory pressure (PImax)
Time Frame: Change from baseline after 3 minutes of exercise
|
The maximum inspiratory pressure (PImax) will be measured during a sniff manoeuvre.
These measurements will allow to construct the ratio of respiratory effort (tidal Pes/PImax) to thoracic displacement (VT/predicted VC), an index of neuromechanical coupling
|
Change from baseline after 3 minutes of exercise
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: François Maltais, M.D, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (ANTICIPATED)
July 1, 2014
Study Completion (ANTICIPATED)
July 1, 2014
Study Registration Dates
First Submitted
July 25, 2012
First Submitted That Met QC Criteria
July 31, 2012
First Posted (ESTIMATE)
August 1, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
September 18, 2013
Last Update Submitted That Met QC Criteria
September 17, 2013
Last Verified
September 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Signs and Symptoms, Respiratory
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Dyspnea
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Reproductive Control Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Tocolytic Agents
- Albuterol
- Ipratropium
Other Study ID Numbers
- CODEX-20819
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyspnea
-
Assistance Publique - Hôpitaux de ParisRecruitingDyspnea Invasive Mechanical Ventilation-associatedFrance
-
Mayo ClinicCompletedShortness of Breath | Cardiac; DyspneaUnited States
-
Qure Healthcare, LLCJohnson & Johnson Pharmaceutical Research & Development, L.L.C.CompletedDyspnea | Unexplained Chronic DyspneaUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedRelationship Between Dyspnea and Ventilatory VariabilityFrance
-
University of MonastirCompleted
-
University of California, Los AngelesNot yet recruitingShortness of Breath/Dyspnea
-
Assistance Publique - Hôpitaux de ParisRecruitingDyspnea and Respiratory Insufficiency in ChildrenFrance
-
Medical University of ViennaRecruitingEchocardiography | Acute DyspneaAustria
-
Intersection Medical, Inc.CompletedPulmonary Congestion | Dyspnea, | Acute Heart Failure SyndromeUnited States
-
University of CologneTeva Branded Pharmaceutical Products R&D, Inc.CompletedCancer | Dyspnea, ParoxysmalGermany
Clinical Trials on Combination ipratropium/salbutamol or placebo (nebulization)
-
Laval UniversityPfizer; Boehringer IngelheimCompletedPhysical Activity | Respiratory Symptoms | Mild Chronic Obstructive Pulmonary DiseaseCanada
-
Hat Yai Medical Education CenterRecruitingAsthma | Airway Obstruction | Airway Remodeling | Parasympathetic Nervous System DiseasesThailand
-
Universidade Federal do Rio Grande do NorteUnknown
-
Verona Pharma plcCompletedChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisWithdrawnPulmonary Arterial Hypertension
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingAsthma | Healthy ParticipantsAustralia
-
Laval UniversityInstitut universitaire de cardiologie et de pneumologie de Québec, University...UnknownChronic Obstructive Pulmonary DiseaseCanada
-
Boehringer IngelheimCompleted
-
Neutec Ar-Ge San ve Tic A.ŞWithdrawn